Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Clin Cancer Res. 2019 Apr 5;25(13):3811–3817. doi: 10.1158/1078-0432.CCR-18-3789

Figure 1.

Figure 1.

Response of patients with metastatic or recurrent esophagogastric cancer to nintedanib. A. Kaplan-Meier plot showing progression-free survival (PFS) of 32 patients treated with nintedanib. Median PFS was 1.9 months, and the PFS rate at 6 months was 19%. B. Kaplan-Meier plot of overall survival (OS) of 32 patients treated with nintedanib. Median OS was 14.2 months and the OS rate at 6 months was 74%. C. Best response and genomic alterations for 27 patients with RECIST-evaluable tumors. *Patient had non-target progression of disease. ‡ Patients with FGFR2 amplification.